DUBLIN, Feb. 5, 2015 /PRNewswire/ --
- Fiscal second quarter net sales increased to a second quarter record of $1.07 billion.
- Excluding the effect of the pre-closing debt and equity issuances related to the previously announced acquisition of Omega Pharma NV (“Omega”), fiscal second quarter adjusted net income increased 32% to a second quarter record of $245 million, with adjusted diluted earnings per share of $1.82.
- Reported fiscal second quarter GAAP net income of $70 million and GAAP diluted earnings per share of $0.51.
- Record fiscal second quarter adjusted gross margin of 45.2% (GAAP gross margin of 35.8%) and adjusted operating margin of 29.5% (GAAP operating margin of 17.2%).
- Record second quarter operating cash flow of $273 million.
- Excluding the effect of the pre-closing debt and equity issuances related to Omega, management expects full-year fiscal 2015 adjusted earnings range of $7.25 to $7.45 per diluted share, an increase of 13% to 17% over fiscal 2014 adjusted earnings per share, and GAAP earnings of between $3.66 and $3.86 per diluted share.
Perrigo Company plc (NYSE: PRGO; TASE) today announced results for its second quarter ended December 27, 2014.
Perrigo’s Chairman, President and CEO Joseph C. Papa commented, “The team’s financial performance for the quarter was generally in-line with our expectations, highlighted by record second quarter net sales, adjusted net income and adjusted margins. U.S. OTC grew approximately 2%, and we realized new product sales of $54 million, primarily in the Rx segment.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
